

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

溫州康寧醫院股份有限公司

Incorporated in the People's Republic of China

Wenzhou Kangning Hospital Co., Ltd. (the “Company”) hereby announces that the nomination of Mr. LI Changhao (“李長豪”) as the candidate of a non-executive director and a member of the audit committee of the Company was considered and approved at a meeting of the board of directors of the Company (the “Board”) held on September 16, 2021, with a term commencing from the date of approval at the general meeting of the Company and ending on the expiry of the term of the third session of the Board.

The biographical details of Mr. Li are as follows:

Mr. Li, aged 32, served as the investment manager of SDIC Chuangyi Industry Fund Management Co., Ltd. (國投創益產業基金管理有限公司) from May 2014 to April 2019, and since May 2019, he has served as the vice president of the investment team of SDIC Chuangyi Industry Fund Management Co., Ltd. (國投創益產業基金管理有限公司), mainly responsible for the investment in private equity projects. He has served as a supervisor of Yunnan Aluminum Co., Ltd. (雲南鋁業股份有限公司), a company listed on the Shenzhen Stock Exchange (stock code: 000807.SZ) and engaged in bauxite mining, alumina production, aluminum smelting, aluminum processing and production of carbon used in aluminum, since January 2021. Mr. Li graduated from Beijing University of Posts and Telecommunications with a bachelor's degree in e-commerce and law in September 2012. He graduated from Queen Mary University of London with a master's degree in marketing in December 2013. Mr. Li was accredited as a chartered financial analyst (CFA) by the Chartered Financial Analyst Institute in August 2017, an intermediate analyst by the Ministry of Human Resources and Social Security of the People's Republic of China in December 2017, and a certified financial risk manager (FRM) by the Global Association Risk Professionals in August 2018.

The proposed appointment of Mr. Li is subject to the approval by the shareholders at the general meeting. If the appointment is approved, Mr. Li will enter into a service contract with the Company. Mr. Li will not receive any remuneration from the Company.

Save as disclosed above, Mr. Li does not hold any other positions with the Company or its subsidiaries as of the date of this announcement. Mr. Li neither held any other directorships in the past three years in any public companies the securities of which are listed on any securities market in Hong Kong and/or overseas, nor held any other major appointments and professional qualifications, and he has no relationship with any directors, supervisors, senior management, substantial shareholders or controlling shareholders of the Company.

As of the date of this announcement, Mr. Li has no interest in the shares of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Mr. Li has never been subject to any penalty by China Securities Regulatory Commission or other related securities regulatory authorities or any stock exchange.

Save as disclosed above, the Board is not aware of any other information to be disclosed pursuant to Rule 13.51(2)(h) to 13.51(2)(v) of the Listing Rules or any other matter in relation to Mr. Li that needs to be brought to the attention of the shareholders.

本公司特此公告，董事會並無知悉任何須根據香港證券及期貨條例第13.51(2)(h)至13.51(2)(v)條及任何其他事項，須向股東披露有關徐永鈞先生的資料。

The Company hereby announces that the nomination of Mr. XU Yongjiu (“徐永鈞”) as the candidate of a supervisor of the Company was considered and approved at a meeting of the supervisory committee of the Company (the “supervisory committee”) held on September 16, 2021, with a term commencing from the date of approval at the general meeting of the Company and ending on the expiry of the term of the third session of the Supervisory Committee.

The biographical details of Mr. Xu are as follows:

Mr. Xu, aged 43, has served as a director, member of the investment committee and senior partner of Shanghai Jinpu Jianfu Equity Investment Management Co., Ltd. since April 2016, mainly responsible for financial and medical investment. From July 2004 to December 2007, he served as the senior investment manager of the Development Research Headquarters of Shanghai International Group. From December 2007 to March 2009, he worked at the Investment Banking Headquarters in Asia Pacific of Citigroup. From March 2009 to September 2011, he served as an executive director of Shanghai International Group and the Securities Investment Headquarters of Shanghai Trust. From October 2011 to October 2015, Mr. Xu served as an executive director of GP Capital Co., Ltd. (

a director of Chengdu Yining Hospital Co., Ltd. (成都怡寧醫院有限公司). Since June 2021, he has been the representative appointed by the managing partners of Wenzhou Jinning Equity Investment Partnership (Limited Partnership) (溫州金寧股權投資合夥企業(有限合夥)). Mr. Xu graduated from Southwestern University of Finance and Economics with a bachelor's degree in economics in July 2000. He graduated from Fudan University with a master's degree in finance in June 2004. Since June 2019, he has attended EMBA (Executive Master of Business Administration) at China Europe International Business School.

The proposed appointment of Mr. Xu is subject to the approval by the shareholders at the general meeting. If the appointment is approved, Mr. Xu will enter into a service contract with the Company. Mr. Xu will not receive any remuneration from the Company.

Save as disclosed above, Mr. Xu does not hold any other positions with the Company or its subsidiaries as of the date of this announcement. Mr. Xu neither held any other directorships in the past three years in any public companies the securities of which are listed on any securities market in Hong Kong and/or overseas, nor held any other major appointments and professional qualifications, and he has no relationship with any directors, supervisors, senior management, substantial shareholders or controlling shareholders of the Company.

As of the date of this announcement, Mr. Xu has no interest in the shares of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Mr. Xu has never been subject to any penalty by China Securities Regulatory Commission or other related securities regulatory authorities or any stock exchange.

The Company will convene an extraordinary general meeting to approve the election of director and supervisor. A circular containing, among others, the information in relation to the proposed election of director and supervisor and a notice of the extraordinary general meeting, will be dispatched to the shareholders of the Company in due course.

In view of the recent share transfer by shareholders of domestic shares of the Company, combined with their actual shareholding in the Company, the Board has proposed to amend the articles of association of the Company (the “Articles of Association”)

Details of the proposed amendments are as follows:

	Amendment to the Articles of Association	Amendment to the Articles of Association
	 The Company repurchased 899,700 H shares as approved by the Company's first extraordinary general meeting for the year 2020, the first Domestic Shareholders' Class Meeting for the year 2020, and the first H Shareholders' Class Meeting for the year 2020, which were all held on March 9, 2020. Upon completion of cancellation of the aforesaid share repurchase, the Company has a registered capital of RMB74,600,300. The shareholding structure is as follows: 74,600,300 ordinary shares, comprising 19,340,300 H shares and 55,260,000 domestic shares, which include:	 The Company repurchased 899,700 H shares as approved by the Company's first extraordinary general meeting for the year 2020, the first Domestic Shareholders' Class Meeting for the year 2020, and the first H Shareholders' Class Meeting for the year 2020, which were all held on March 9, 2020. Upon completion of cancellation of the aforesaid share repurchase, the Company has a registered capital of RMB74,600,300. The shareholding structure is as follows: 74,600,300 ordinary shares, comprising 19,340,300 H shares and 55,260,000 domestic shares, which include:

1.	Guan Weili	18,350,250	24.5981%	1.	Guan Weili	18,350,250	24.5981%
2.	Guangzhou GL Capital Investment Fund L.P. (廣州德福股權投資基金合夥企業(有限合夥))	15,384,541	20.6226%	2.	Guangzhou GL Capital Investment Fund L.P. (廣州德福股權投資基金合夥企業(有限合夥))	15,384,541	20.6226%
3.	Wang Hongyue	3,984,350	5.3409%	3.	Wang Hongyue	3,984,350	5.3409%
4.	Wang Lianyue	3,794,500	5.0864%	4.	Wang Lianyue	3,794,500	5.0864%
5.	Shanghai Tanying Investment L.P. (上海檀英投資合夥企業(有限合夥))	3,253,180	4.3608%	5.	Shanghai Tanying Investment L.P. (上海檀英投資合夥企業(有限合夥))	3,253,180	4.3608%
6.	Shanghai Qiangang Investment Management L.P. (上海乾剛投資管理合夥企業(有限合夥))	3,253,179	4.3608%	6.	Shanghai Qiangang Investment Management L.P. (上海乾剛投資管理合夥企業(有限合夥))	3,253,179	4.3608%
7.	Qingdao Jinshi Haona Investment Co., Ltd. (青島金石灝納投資有限公司)	2,780,000	3.7265%	7.	Qingdao Jinshi Haona Investment Co., Ltd. (青島金石灝納投資有限公司)	2,780,000	3.7265%
8.	Ningbo Xinshi Kangning Investment Management L.P. (寧波信實康寧投資管理合夥企業(有限合夥))	1,543,000	2.0684%	8.	Ningbo Xinshi Kangning Investment Management L.P. (寧波信實康寧投資管理合夥企業(有限合夥))	1,543,000	2.0684%
9.	Ningbo Enci Kangning Investment Management L.P. (寧波恩慈康寧投資管理合夥企業(有限合夥))	258,000	0.3458%	9.	Ningbo Enci Kangning Investment Management L.P. (寧波恩慈康寧投資管理合夥企業(有限合夥))	258,000	0.3458%
10.	Ningbo Renai Kangning Investment Management L.P. (寧波仁愛康寧投資管理合夥企業(有限合夥))	199,000	0.2668%	10.	Ningbo Renai Kangning Investment Management L.P. (寧波仁愛康寧投資管理合夥企業(有限合夥))	199,000	0.2668%
11.	Wenzhou Zhenyan Kangning Investment Management L.P. (溫州箴言康寧投資管理合夥企業(有限合夥))	804,794	1.0788%	11.	Wenzhou Zhenyan Kangning Investment Management L.P. (溫州箴言康寧投資管理合夥企業(有限合夥))	804,794	1.0788%
12.	Wenzhou Jiamei Kangning Investment Management L.P. (溫州迦美康寧投資管理合夥企業(有限合夥))	788,921	1.0575%	12.	Wenzhou Jiamei Kangning Investment Management L.P. (溫州迦美康寧投資管理合夥企業(有限合夥))	788,921	1.0575%

	Wenzhou Enquan Kangning Investment Management L.P. (溫州恩泉康寧投資管理合夥企業(有限合夥))				Wenzhou Enquan Kangning Investment Management L.P. (溫州恩泉康寧投資管理合夥企業(有限合夥))		
13.	Wenzhou Enquan Kangning Investment Management L.P. (溫州恩泉康寧投資管理合夥企業(有限合夥))	407,832	0.5467%	13.	Wenzhou Enquan Kangning Investment Management L.P. (溫州恩泉康寧投資管理合夥企業(有限合夥))	407,832	0.5467%
14.	Wenzhou Jiatai Kangning Investment Management L.P. (溫州迦特康寧投資管理合夥企業(有限合夥))	267,431	0.3585%	14.	Wenzhou Jiatai Kangning Investment Management L.P. (溫州迦特康寧投資管理合夥企業(有限合夥))	267,431	0.3585%
15.	Wenzhou Shouwang Kangning Investment Management L.P. (溫州守望康寧投資管理合夥企業(有限合夥))	191,022	0.2561%	15.	Wenzhou Shouwang Kangning Investment Management L.P. (溫州守望康寧投資管理合夥企業(有限合夥))	191,022	0.2561%
16.	Public shareholders of H shares	19,340,300	25.9252%	16.	Public shareholders of H shares	19,340,300	25.9252%
Total		74,600,300	100.0000%	Total		74,600,300	100.0000%
				0 (廣州德禧股權投資基金合夥企業(有限合夥)) ,000 (萬得影響力股權投資(嘉興)合夥企業(有限合夥)) (中			


一、按地区分布		二、按行业分布	
地区/行业	金额	占比	占比
华东地区	1,234,567.89	34.56%	34.56%
华南地区	987,654.32	28.75%	28.75%
华北地区	765,432.10	22.34%	22.34%
华中地区	543,210.98	15.67%	15.67%
西南地区	321,098.76	9.45%	9.45%
西北地区	109,876.54	3.23%	3.23%
东北地区	87,654.32	2.56%	2.56%
海外地区	65,432.10	1.91%	1.91%
合计	3,567,890.12	100.00%	100.00%
医药制造业	2,345,678.90	65.78%	65.78%
医药批发业	1,234,567.89	34.56%	34.56%
医药零售业	987,654.32	28.75%	28.75%
医药服务业	765,432.10	22.34%	22.34%
其他行业	543,210.98	15.67%	15.67%
合计	3,567,890.12	100.00%	100.00%

In respect of the proposed amendments to the Articles of Association, one article is amended, and no article is added or deleted. The number of the articles of the amended Articles of Association remains the same.

The resolution has been approved by the Board, and a special resolution will be proposed at the extraordinary general meeting to approve, among other things, the above proposed amendments to the Articles of Association. A circular containing, among other things, details of the proposed amendments to the Articles of Association and notice of the extraordinary general meeting will be dispatched to the shareholders of the Company in due course.

The amended Articles of Association shall become effective on the date of passing the relevant resolution at the extraordinary general meeting. Prior to the passing of the relevant resolution at the extraordinary general meeting, the prevailing Articles of Association of the Company shall remain valid.

By order of the Board


Chairman

Zhejiang, the PRC
September 16, 2021

As of the date of this announcement, the executive Directors are Mr. GUAN Weili, Ms. WANG Lianyue and Ms. WANG Hongyue; the non-executive Director is Mr. QIN Hao; and the independent non-executive Directors are Mr. ZHAO Xudong, Ms. ZHONG Wentang and Mr. LIU Ning.